CD274 and neoplasm: Increasing evidence suggests that PD-L1 expression and the broader tumor immune microenvironment—including the density and spatial distribution of tumor-infiltrating lymphocytes—also modulate the efficacy of checkpoint blockade.17) In the present case, we did not evaluate PD-L1 expression, tumor-infiltrating lymphocyte density, or their spatial organization, and therefore the immune context in which durvalumab was administered cannot be fully characterized.